Hcw Biologics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Form 4: HCW Biologics CEO Buys Shares
Hing C Wong, Chief Executive Officer, a Director and 10% owner of HCW Biologics Inc., purchased 23,210 shares of common stock on July 29, 2026 for $2.58 per share.
NASDAQ
Lee Flowers, SVP of Business Development of HCW Biologics Inc., purchased 7,736 shares of common stock on July 29, 2026 for $2.58 per share.
NASDAQ
Scott T Garrett, a Director of HCW Biologics Inc., purchased 7,736 shares of common stock on July 29, 2026 for $2.58 per share.
NASDAQ
CEO Hing C. Wong acquired 113,879 shares and matching warrants in a private placement transaction.
NASDAQ
Director Scott T. Garrett acquired 177,936 shares and matching warrants of HCW Biologics Inc. in a private placement.
NASDAQ
HCW Biologics CFO Rebecca Byam acquired 14,235 shares and associated warrants in a private placement transaction.
NASDAQ
Hing C. Wong, CEO of HCW Biologics Inc., acquired 8,054 shares of common stock through the conversion of unsecured convertible promissory notes.
NASDAQ
Gary M. Winer, a director of HCW Biologics Inc., acquired 1,342 shares of common stock through the conversion of unsecured convertible promissory notes.
NASDAQ
Scott T. Garrett, a director at HCW Biologics, acquired 13,423 shares of common stock through the conversion of unsecured convertible promissory notes.
NASDAQ
Director Gary M. Winer reports acquisition and disposal of HCW Biologics Inc. common stock and warrants related to a secured notes conversion.
NASDAQ
Form 4: HCW Biologics CEO Hing C. Wong Reports Acquisition of Shares and Warrants Through Debt Conversion
Hing C. Wong, CEO of HCW Biologics Inc., reports acquiring shares and warrants following a debt conversion agreement.
NASDAQ
Director Garrett Scott T acquired HCW Biologics shares and warrants through the conversion of secured notes.
NASDAQ
Rebecca Byam, CFO of HCW Biologics Inc., reports acquisition and disposal of company stock and warrants related to a secured notes conversion.
NASDAQ
Lee Flowers, SVP of Business Development at HCW Biologics, acquired shares and warrants through the conversion of secured notes.
NASDAQ
Director Rick S. Greene reports acquiring HCW Biologics common stock and warrants through the conversion of secured notes.
NASDAQ
Director Lisa M. Giles acquired stock options for 12,500 shares of HCW Biologics Inc. on June 14, 2024.
NASDAQ
Director Scott T. Garrett acquired stock options in HCW Biologics Inc. on June 14, 2024.
NASDAQ
Director Rick S. Greene of HCW Biologics Inc. acquired stock options for 12,500 shares on June 14, 2024.
NASDAQ
Gary M. Winer, a director at HCW Biologics Inc., acquired stock options for 12,500 shares on June 14, 2024.